Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arcutis Biotherapeutics Completes Enrollment For Phase 1b Study Of ARQ-255, A JAK1 Inhibitor Topical Suspension For Alopecia Areata; Phase 1b Results Expected In First Half Of 2025

Author: Benzinga Newsdesk | September 05, 2024 08:06am

Posted In: ARQT